1. Scrip
  2. >>COVID-19

Vir Advances Antibodies Against COVID-19, CEO Scangos Leads BIO’s Coronavirus Outreach

 
• By Mandy Jackson

Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.

3DCoronavirus
Vir generated antibodies against coronaviruses before the COVID-19 pandemic • Source: Shutterstock

George Scangos made a surprising shift when the former Biogen CEO left the world of big biotech to lead an infectious disease-focused start-up. Vir Biotechnology Inc. emerged in early 2017 with $150m and quickly brought its fundraising total later that year to more than $500m. The company went public late last year and Vir’s participation in the search for a coronavirus treatment has thrust the company into the spotlight in the last month, and elevated Scangos’s profile once again since he’s also leading BIO’s outreach to biotech firms to help get their coronavirus ideas from concept to clinical trials.

Vir’s stock has surged from $12.15 at the start of the year to $39

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.